Precision BioSciences (NASDAQ:DTIL) CEO Michael Amoroso Sells 34,799 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 34,799 shares of Precision BioSciences stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $4.17, for a total transaction of $145,111.83. Following the transaction, the chief executive officer owned 196,154 shares of the company’s stock, valued at $817,962.18. This represents a 15.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 3rd, Michael Amoroso sold 3,409 shares of Precision BioSciences stock. The stock was sold at an average price of $6.49, for a total value of $22,124.41.

Precision BioSciences Trading Up 6.0%

NASDAQ:DTIL traded up $0.24 during midday trading on Thursday, reaching $4.25. 319,633 shares of the stock traded hands, compared to its average volume of 250,309. The company has a fifty day moving average of $4.59 and a 200 day moving average of $5.12. The stock has a market capitalization of $56.36 million, a P/E ratio of -0.51 and a beta of 1.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 3.45 and a current ratio of 3.45. Precision BioSciences, Inc. has a 12 month low of $3.75 and a 12 month high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.53). Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $5.40 million. During the same period in the prior year, the company earned ($2.25) earnings per share. On average, research analysts predict that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Precision BioSciences currently has an average rating of “Hold” and a consensus target price of $60.00.

Institutional Investors Weigh In On Precision BioSciences

Several large investors have recently bought and sold shares of DTIL. Vanguard Personalized Indexing Management LLC purchased a new stake in Precision BioSciences in the 3rd quarter valued at $72,000. Virtu Financial LLC purchased a new position in Precision BioSciences in the third quarter valued at $84,000. GSA Capital Partners LLP purchased a new stake in shares of Precision BioSciences in the 3rd quarter valued at approximately $98,000. Velan Capital Investment Management LP acquired a new stake in shares of Precision BioSciences during the 3rd quarter worth about $110,000. Finally, Citadel Advisors LLC acquired a new stake in Precision BioSciences during the 3rd quarter worth $122,000. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.